1. Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses.
- Author
-
Kadra-Scalzo G, Ahn D, Bird A, Broadbent M, Chang CK, Pritchard M, Shetty H, Taylor D, Hayes R, and Stewart R
- Subjects
- Adult, Humans, London, Paliperidone Palmitate therapeutic use, Patient Acceptance of Health Care, Antipsychotic Agents therapeutic use, Schizophrenia drug therapy
- Abstract
Objectives: To compare mental healthcare use and healthcare professional (HCP) contacts for patients before and after initiation of paliperidone palmitate., Setting: The South London and Maudsley NHS Foundation Trust (SLAM) Biomedical Research Centre Clinical Record Interactive Search., Participants: We identified all adults with a diagnosis of schizophrenia (International Classification of Diseases 10th Revision: F20.x), who had received paliperidone palmitate prescription for at least 365 days and had at least 1 year of recorded treatment from SLAM, prior to the first recorded receipt of paliperidone palmitate., Primary and Secondary Outcome Measures: Inpatient and community mental healthcare service use, such as inpatient bed days, number of active days in the service, face-to-face and telephone HCP use in the 12 months before and after paliperidone palmitate initiation., Results: We identified 664 patients initiated on paliperidone palmitate. Following initiation, inpatient bed days were lower, although patients remained active on the service case load longer for both mirror approach 1 (mean difference of inpatient bed days -10.48 (95% CI -15.75 to -5.22); days active 40.67 (95% CI 33.39 to 47.95)) and mirror approach 2 (mean difference of inpatient bed days -23.96 (95% CI -30.01 to -17.92); mean difference of days active 40.69 (95% CI 33.39 to 47.94)). The postinitiation period was further characterised by fewer face-to-face and telephone contacts with medical and social work HCPs, and an increased contact with clinical psychologists., Conclusions: Our findings indicate a change in the profile of HCP use, consistent with a transition from treatment to possible rehabilitation., Competing Interests: Competing interests: RH, C-KC, HS and RS have received research funding from Roche, Pfizer, Janssen and Lundbeck. GK-S has received funding from Janssen and Lundbeck. RS has also received research funding from Takeda. AB is an employee of Janssen UK. DT has received investigator-initiated research grants from AstraZeneca, Eli Lilly, Janssen, Lundbeck, Otsuka, Servier and Sunovion. RH, RS, HS, C-KC and GK-S receive salary support from the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. DT is a pharmacist and clinical academic at the South London and Maudsley Hospital NHS Trust and King’s College London., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF